Na Li
Vice President, DMPK Cellarity
Na Li is a Vice President, DMPK at Cellaritybio, where she leads the Drug Metabolism and Pharmacokinetics (DMPK) department. Her role involves overseeing the development and application of DMPK modeling and simulation techniques to optimize drug development processes. Na Li has a strong background in drug discovery and has been involved in various projects that have contributed to the advancement of DMPK methodologies. Her expertise in this field is crucial for the company’s mission to develop innovative therapeutics that address complex diseases.
Seminars
Thursday 22nd October 2026
DMPK Strategy for Irreversible Covalent Inhibitor to Guide the Translation From Preclinical to Human
2:00 pm
- DCN1, a novel target for fetal hemoglobin induction for Sickle cell disease, was discovered by the innovative transcriptomic platform at Cellarity
- Covalent inhibition of DCN1 was designed to achieve the desired pharmacology
- Developing IVIVE strategy to predict human clearance of covalent inhibitors and applying target turnover informed PK/PD model for predicting human efficacious dose
- Integrating PK/PD modeling with target occupancy data to guide the translation from preclinical models to human
